SANUWAVE Health, Inc. (SNWV) Form 10-Q — Aug 6, 2026
SANUWAVE Health reported second-quarter 2026 revenue of $9.7 million, down about 3% from $10.1 million a year earlier, as UltraMIST system sales fell roughly 34% to $2.3 million while consumables revenue grew 12% to $7.3 million. The company swung to a net loss of $682,000, or $0.08 per share, versus restated net income of $551,000 in the prior-year quarter, driven by an operating loss as R&D, selling, and G&A costs rose.
Key figures
- Revenue
- 9739000
- Revenue Yoy
- -3%
- Total Assets
- 36605000
- Cash Position
- 9376000
- Shares Outstanding
- 8602309
- Revolver drawn
- 655000
- Six month revenue
- 19358000
- System revenue q2
- 2288000
- Stockholders equity
- 2787000
- Term loan principal
- 18687000
- Consumables revenue q2
- 7325000
- Unrecognized stock comp
- 10600000
- Q2 gross margin pct 2026
- 76
- Restated q2 2025 revenue
- 10054000
- Restated q2 2025 net income
- 551000
- Term loan current maturities
- 5750000
- Six month operating cash flow
- 822000
- Q2 gross margin pct 2025 restates
- 78
Price after filing
1 day: 0.0%7 days: -20.1%30 days: -26.6%
Close on the filing date to close N calendar days later (from $5.97). Historical, not a forecast.
AI analysis
Red flags5 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.